Patient Assistance Program Administration
Access to optimal cancer treatments is critical to improving the lives of cancer
survivors in every country around the world. The Max Foundation is committed to
helping people living with cancer navigate their local healthcare systems to facilitate
access to treatment and support.
There are various paths to treatment access, such as through government programs,
clinical trials, or through Patient Assistance Programs (PAPs), also known as drug
Since 2001, The Max Foundation has partnered in the administration of Novartis’
Glivec International Patient Assistance Program (GIPAP), an unparalleled drug access
program for Glivec. The Max Foundation now supports the administration of other
Novartis Oncology Access programs in countries such as Malaysia, India and Thailand.
In addition to helping guide patients and their doctors through the PAP enrollment
process, The Max Foundation provides program beneficiaries including their family
members, with free services of emotional support, informational referrals and advocacy.
For more information, please click on the links provided below:
GIPAP | What
is GIPAP | What is Glivec |
GIPAP Qualification Requirements | Physician
Instructions | GIPAP FAQ |